, and on the right hand, 1.1cm x 0.9 cm). All these lesions were excised with free margins and HP results confirmed the following: basocellular carcinoma (BCC), SCC in situ and G1 CSCC, respectively.
All these changes were located in places exposed to UV radiation. In September 2018, another skin change appeared in this patient, in the left shoulder area. The tumor grew rapidly and in February 2019 it achieved a size of 10 cm x 10 cm x 5 cm. It was surgically removed and HP examination revealed a keratoacanthoma (Figure 1 A-D) . During the observation period the patient presented good general health. Due to triple drug immunosuppression, oncological monitoring was performed and no other proliferative lesions were found. At the beginning of April 2019 she developed bronchitis followed by bronchopneumonia. As there was no improvement of pneumonia, lung CT scan was performed that revealed very numerous coin lesions in both lungs. Due to the advanced stage of the process, diagnostic procedures were limited to cytology of pleural fluid and talc pleurodesis. HP examination revealed lung adenocarcinoma with p40(-), TTF-1(+++) pattern. 2 weeks later the patient died due to respiratory insufficiency.
BCC, CSCC and keratoacanthoma are common non-melanoma skin cancers. Several studies confirmed that immunosuppressive agents used after organ transplantation devitalize anti-tumor action of immune cells thus increasing the risk of skin cancer development, as compared to the healthy population [1] . It is worth mentioning that the symptom of spontaneous or touch pain which is not very characteristic in the general population, is a significant indicator of the development of the invasive form of squamous cell carcinoma (SCC) [2, 3] . In this case a primary pulmonary adenocarcinoma developed in the patient with a smoking history 4years after transplantation.
Appearance of keratoacanthoma in transplant recipients should arouse physicians to conduct prompt and insightful oncological screening, because such phenomenon is connected with higher risk of posttransplant malignancy and death [4, 5] . 
